In the most recent trading session, Adma Biologics (ADMA) closed at $18.34, indicating a +1.72% shift from the previous trading day.
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical compan
Texas Permanent School Fund Corp trimmed its stake in ADMA Biologics Inc (NASDAQ: ADMA) by 39.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
AWM Investment Company Inc. lowered its position in ADMA Biologics Inc (NASDAQ: ADMA) by 9.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commis
Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.
Federated Hermes Inc. trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ: ADMA) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securitie
Ardsley Advisory Partners LP lifted its position in ADMA Biologics Inc (NASDAQ: ADMA) by 33.3% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund o
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Creative Planning reduced its stake in shares of ADMA Biologics Inc (NASDAQ: ADMA) by 10.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Ex
Advantage Alpha Capital Partners LP cut its stake in shares of ADMA Biologics Inc (NASDAQ: ADMA) by 58.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The i
The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
American Century Companies Inc. raised its stake in ADMA Biologics Inc (NASDAQ: ADMA) by 8.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE